Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases
- 259 Downloads
Purpose. Because the urinary excretion of drugs is often decreased in renal diseases, dosage regimens are adjusted to avoid adverse drug reactions. The aim of present study was to clarify the alteration in the levels of renal drug transporters and their correlation with the urinary drug excretion in renal diseases patients.
Methods. We quantified the mRNA levels of human organic anion transporters (hOATs) by real-time polymerase chain reaction and examined the excretion of the anionic drug, cefazolin, in renal disease patients. Moreover, transport of cefazolin by hOAT1 and hOAT3 were examined using HEK293 transfectants.
Results. Among four hOATs, the level of hOAT1 mRNA was significantly lower in the kidney of patients with renal diseases than in the normal controls. The elimination constant of cefazolin showed a significant correlation with the values of phenolsulfonphthalein test and mRNA levels of hOAT3. The uptake study using HEK293 transfectants revealed that cefazolin and phenolsulfonphthalein were transported by hOAT3.
Conclusions. These results suggest that hOAT3 plays an important role for anionic drug secretion in patients with renal diseases and that the expression levels of drug transporters may be related to the alteration of renal drug secretion.
Unable to display preview. Download preview PDF.
- 1.L. Dettli. Drug dosage in renal disease. Clin. Pharmacokinet. 1:126-134 (1976).Google Scholar
- 2.R. Hori, K. Okumura, A. Kamiya, H. Nihira, and H. Nakano. Ampicillin and cephalexin in renal insufficiency. Clin. Pharmacol. Ther. 34:792-798 (1983).Google Scholar
- 3.R. Hori, K. Okumura, H. Nihira, H. Nakano, K. Akagi, and A. Kamiya. A new dosing regimen in renal insufficiency: application to cephalexin. Clin. Pharmacol. Ther. 38:290-295 (1985).Google Scholar
- 4.J. V. Moller and M. I. Sheikh. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacol. Rev. 34:315-358 (1982).Google Scholar
- 5.G. Burckhardt and N. A. Wolff. Structure of renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol. 278:F853-F866 (2000).Google Scholar
- 6.K. Inui, S. Masuda, and H. Saito. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58:944-958 (2000).Google Scholar
- 7.T. Sekine, S. H. Cha, and H. Endou. The multispecific organic anion transporter (OAT) family. Pflugers Arch. 440:337-350 (2000).Google Scholar
- 8.M. Hosoyamada, T. Sekine, Y. Kanai, and H. Endou. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276:F122-F128 (1999).Google Scholar
- 9.R. Lu, B. S. Chan, and V. L. Schuster. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am. J. Physiol. 276:F295-F303 (1999).Google Scholar
- 10.H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K. Inui. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13:866-874 (2002).Google Scholar
- 11.A. Enomoto, M. Takeda, M. Shimoda, S. Narikawa, Y. Kobayashi, T. Yamamoto, T. Sekine, S. H. Cha, T. Niwa, and H. Endou. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J. Pharmacol. Exp. Ther. 301:797-802 (2002).Google Scholar
- 12.S. H. Cha, T. Sekine, J. Fukushima, Y. Kanai, Y. Kobayashi, T. Goya, and H. Endou. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol. 59:1277-1286 (2001).Google Scholar
- 13.D. H. Sweet, D. S. Miller, J. B. Pritchard, Y. Fujiwara, D. R. Beier, and S. K. Nigam. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. 277:26934-26943 (2002).Google Scholar
- 14.E. Babu, M. Takeda, S. Narikawa, Y. Kobayashi, A. Enomoto, A. Tojo, S. H. Cha, T. Sekine, D. Sakthisekaran, and H. Endou. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim. Biophys. Acta 1590:64-75 (2002).Google Scholar
- 15.Y. Urakami, M. Akazawa, H. Saito, M. Okuda, and K. Inui. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703-1710 (2002).Google Scholar
- 16.M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254 (1976).Google Scholar
- 17.M. Takeda, S. Narikawa, M. Hosoyamada, S. H. Cha, T. Sekine, and H. Endou. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur. J. Pharmacol. 419:113-120 (2001).Google Scholar
- 18.K. Takahashi, S. Masuda, N. Nakamura, H. Saito, T. Futami, T. Doi, and K. Inui. Upregulation of H+-peptide cotransporter PEPT2 in rat remnant kidney. Am. J. Physiol. Renal Physiol. 281:F1109-F1116 (2001).Google Scholar
- 19.A. Takeuchi, S. Masuda, H. Saito, T. Doi, and K. Inui. Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney Int. 60:1058-1068 (2001).Google Scholar
- 20.L. Ji, S. Masuda, H. Saito, and K. Inui. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int. 62:514-524 (2002).Google Scholar
- 21.E. K. Brodwall, T. Bergan, and O. Ørjavik. Kidney transport of cefazolin in normal and impaired renal function. J. Antimicrob. Chemother. 3:585-592 (1977).Google Scholar
- 22.G. R. Brown. Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. 24:289-300 (1993).Google Scholar
- 23.M. I. Sheikh. Renal handling of phenol red. I. A comparative study on the accumulation of phenol red and p-aminohippurate in rabbit kidney tubules in vitro. J. Physiol. 227:565-590 (1972).Google Scholar
- 24.S. Jariyawat, T. Sekine, M. Takeda, N. Apiwattanakul, Y. Kanai, S. Sophasan, and H. Endou. The interaction and transport of β-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther. 290:672-677 (1999).Google Scholar
- 25.K. Y. Jung, M. Takeda, M. Shimoda, S. Narikawa, A. Tojo, K. Kim do, A. Chairoungdua, B. K. Choi, H. Kusuhara, Y. Sugiyama, T. Sekine, and H. Endou. Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 70:1861-1874 (2002).Google Scholar
- 26.M. Takeda, E. Babu, S. Narikawa, and H. Endou. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. 438:137-142 (2002).Google Scholar
- 27.Y. Uwai, H. Saito, and K. Inui. Rat renal organic anion transporter rOAT1 mediates transport of urinary-extreted cephalosporins, but not of biliary-extracted cefoperazon. Drug. Metabol. Pharmacokin. 17:125-129 (2002).Google Scholar
- 28.M. Burg, L. Stoner, J. Cardinal, and N. Green. Furosemide effect on isolated perfused tubules. Am. J. Physiol. 225:119-124 (1973).Google Scholar
- 29.J. F. Seely and J. H. Dirks. Site of action of diuretic drugs. Kidney Int. 11:1-8 (1977).Google Scholar
- 30.Y. Uwai, H. Saito, Y. Hashimoto, and K. Inui. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J. Pharmacol. Exp. Ther. 295:261-265 (2000).Google Scholar